Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension

American Journal of Hypertension

Volumn 21, Issue 6, 2008, Pages 674-678

  Pretnar Oblak, Janja ^a   Sebestjen, Miran ^a   Sabovic, Miso ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARGININE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRIMIDONE;

ADULT; AGED; ARTERY DILATATION; ARTICLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; BRAIN CIRCULATION; BRAIN CORTEX; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPEREMIA; HYPERTENSION; MALE; MIDDLE CEREBRAL ARTERY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ARGININE; BLOOD CIRCULATION; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; PYRROLES; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 44349111370     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.153     Document Type: Article

References (23)

1. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
2. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902-2909.
3. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
4. Carod-Artal FJ. Statins and cerebral vasomotor reactivity: implications for a new therapy? Stroke 2006; 37:2446-2448.
5. Olsson A, Casciano R, Stern L, Svangren P. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 2004; 96:51-57.
6. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006; 37:2640-2643.
7. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005; 1:29-40.
8. Micieli G, Bosone D, Zappoli F, Marcheselli S, Argenteri A, Nappi G. Vasomotor response to CO2 and L-arginine in patients with severe internal carotid artery stenosis; pre- and post-surgical evaluation with transcranial Doppler. J Neurol Sci 1999; 163:153-158.
9. Zimmermann C, Wimmer M, Haberl RL. L-arginine-mediated vasoreactivity in patients with risk of stroke. Cerebrovasc Dis 2004; 17:128-133.
10. Pretnar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M. Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 2006; 37:2540-2545.
11. Droste DW, Ritter MA, Dittrich R, Heidenreich S, Wichter T, Freund M, Ringelstein EB. Arterial hypertension and ischaemic stroke. Acta Neurol Scand 2003; 107:241-251.
12. Green R, Kwok S, Durrington PN. Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM 2002; 95: 821-826.
13. Cosentino F, Francia P, Musumeci B, De Siati L, Rao MA, De Luca N, Balla C, De Sensi F, Volpe M. Nitric oxide release is impaired in hypertensive individuals with familial history of stroke. Am J Hypertens 2006; 19:1213-1216.
14. Zvan B, Zaletel M, Pogacnik T, Kiauta T. Testing of cerebral endothelium function with L-arginine after stroke. Int Angiol 2002; 21:256-259.
15. Okamoto M, Etani H, Yagita Y, Kinoshita N, Nukada T. Diminished reserve for cerebral vasomotor response to L-arginine in the elderly: evaluation by transcranial Doppler sonography. Gerontology 2001; 47:131-135.
16. Raitakari O, Celermajer DS. Testing for endothelial dysfunction. Ann Med 2000; 32:293-304.
17. Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res 2007; 1169:125-132.
18. Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol 2006; 176:1-40.
19. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000; 20:131-147.
20. Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 2000; 20:231-253.
21. Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T, Qiu J, Amin-Hanjani S, Huang PL, Liao JK, Lo EH, Moskowitz MA. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab 2005; 25:722-729.
22. Martinez-Gonzalez J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des 2007; 13:1771-1786.
23. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke. Stroke 2007; 38:2652-2657.